Why the study?
The study was designed to probe the cardioprotective effects of nanoyttria against isoproterenol-induced cardiac injury.
Does nanoyttria reduce isoproterenol-induced cardiac injury in mice?
Does nanoyttria reduce isoproterenol-induced cardiac injury in mice?
Nanoyttria demonstrates cardioprotective, anti-inflammatory, and antifibrotic effects in a mouse model of isoproterenol-induced cardiac injury.
AIM: The present study was designed to probe the cardioprotective effects of nanoyttria (NY). MATERIALS & METHODS: NY was characterized using various techniques. Isoproterenol (ISO)-induced cardiotoxicity challenged mice were treated with NY for 28 days at two doses (0.4 and 4 mg/kg, intraperitoneally). RESULTS: NY demonstrated free radical scavenging activity as shown by a 2,2-diphenyl-1-picrylhydrazyl assay. NY treatment showed alleviation of ISO-induced cardiotoxicity as evident from the reduction in biochemical parameters. The expression of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) showed significant decrease upon NY treatment. Histopathology and ECG showed protection in histoarchitecture and rhythm of heart, respectively. Reduction in hydroxyproline and TGF-β1 expression indicated antifibrotic activity. CONCLUSION: We report for the first time that NY ameliorates ISO-induced cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Godugu et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: